Treatment of Erectile Dysfunction

Initial Evaluation and Treatment Approach

• The American College of Cardiology and other guideline societies recommend that phosphodiesterase type 5 inhibitors (PDE5i) are the first-line treatment for erectile dysfunction (ED), regardless of whether ED is psychological or physical in origin, with lifestyle modifications and risk factor management initiated simultaneously 1, 2, 3
• Psychological ED characteristics include sudden onset of symptoms, early collapse of erection during intercourse, and preserved quality of spontaneous, self-stimulated, or morning erections 4, 5, 3
• Physical/Organic ED characteristics include gradual onset over time, lack of tumescence in all situations, and risk factors such as cardiovascular disease, diabetes, hypertension, and neurological conditions 4, 5, 3

Lifestyle Modifications and Risk Factor Management

• The National Comprehensive Cancer Network recommends lifestyle modifications, including smoking cessation, weight loss if BMI >30 kg/m², increased physical activity, reduced alcohol consumption, and improved glycemic control in diabetics 1, 2, 3, 4
• Optimization of blood pressure and lipid management is also recommended 3

Pharmacotherapy

• PDE5i (sildenafil, tadalafil, vardenafil, avanafil) are effective for both psychological and organic ED, with 60-65% of men achieving successful intercourse 1, 2
• The dosing strategy for PDE5i includes starting conservatively and titrating to maximum dose, with an adequate trial requiring at least 5 separate occasions at maximum dose before declaring failure 1, 2, 3
• Absolute contraindications for PDE5i include concurrent nitrate use, guanylate cyclase stimulators (riociguat), and certain medications that cause dangerous hypotension 1, 2, 4, 3

Etiology-Specific Additional Interventions

• For psychological ED, referral to sex therapy or couples counseling should occur concurrently with PDE5i initiation, not sequentially 1, 2, 6
• Addressing specific psychiatric conditions, such as generalized anxiety states, depressive illness, and substance use disorders, is also recommended 4, 5, 6, 3
• For physical ED with comorbidities, testosterone replacement therapy may be indicated for documented low testosterone, and medication optimization, such as switching antihypertensives to agents with lower ED risk, may be necessary 3, 4, 5

Second-Line and Third-Line Therapies

• When two different PDE5i trials at maximum dose fail, referral to urology for second-line therapies, such as intraurethral alprostadil suppositories, intracavernous vasoactive drug injection therapy, and vacuum erection devices, may be necessary 1, 2
• Penile prosthesis implantation is reserved for patients who fail all medical therapies and is associated with high satisfaction rates 1, 2

Treatment of Erectile Dysfunction

Lifestyle Modifications

• Smoking cessation is recommended for patients with erectile dysfunction, as it can improve treatment outcomes, according to the Ca-A Cancer Journal for Clinicians 7

Testosterone Replacement Therapy

• Testosterone monotherapy should not be prescribed for men interested in current or future fertility, as stated by The Journal of urology 8

Treatment of Erectile Dysfunction

Pharmacotherapy

• The European Association of Urology recommends available PDE5 inhibitor agents, including Sildenafil, Tadalafil, Vardenafil, and Avanafil, for the treatment of erectile dysfunction 9
• Psychosocial interventions, including sexual skills training and cognitive behavioral therapy, complement medical treatment effectively, as suggested by the European Urology guidelines 9
• Testosterone combined with PDE5Is may help hypogonadal nonresponders, according to the European Urology guidelines 9
• Education about correct dosing and need for sexual stimulation can restore effectiveness in many patients, as stated in the European Urology guidelines 9
• Combination therapies, such as PDE5Is with antioxidants, low-intensity shockwave therapy, or vacuum erection devices, may be considered for PDE5I non-response, as suggested by the European Urology guidelines 9

Second-Line Therapies

• Intracavernous injection therapy with vasoactive drugs, such as alprostadil, papaverine, and phentolamine, remains highly effective, as recommended by the European Urology guidelines 9
• Vacuum erection devices show 90% initial efficacy but drop to 50-64% satisfaction at 2 years, according to the European Urology guidelines 9
• Low-intensity shockwave therapy may benefit mild vasculogenic ED and has shown benefit even in PDE5I nonresponders, as suggested by the European Urology guidelines 9

Diagnostic Considerations

• The American Urological Association suggests distinguishing ED from premature ejaculation in young men, as these conditions frequently coexist and are often confused 10
• If concomitant premature ejaculation exists, the American Urological Association recommends treating the ED first 10

Erectile Dysfunction Treatment Guidelines

Initial Treatment Approach

• The American Urological Association and American College of Cardiology endorse starting with oral PDE5i therapy immediately while addressing modifiable risk factors, as the evidence-based standard of care 11, 12

Essential Baseline Evaluation

• The American Urological Association recommends obtaining morning serum total testosterone level, as a moderate recommendation, before prescribing PDE5i 11, 12
• Cardiovascular risk assessment is essential, as ED is a marker for underlying cardiovascular disease, and ED symptoms typically present 3 years before coronary artery disease symptoms 11, 12

Testosterone Deficiency Considerations

• The American Urological Association suggests that PDE5i combined with testosterone therapy is more effective than PDE5i alone for patients with low testosterone 13

Medication Optimization and Second-Line Therapies

• The American Urological Association recommends reviewing and modifying medications that may cause ED, and considering switching antihypertensives to agents with lower ED risk 13
• Intracavernosal injection therapy, intraurethral alprostadil suppositories, vacuum erection devices, and low-intensity shockwave therapy are second-line therapies for patients who fail PDE5i, with vacuum erection devices having 90% initial efficacy but dropping to 50-64% satisfaction at 2 years 13

Prevention of Complications

• The American Urological Association advises against declaring PDE5i failure prematurely, and against performing penile prosthesis surgery in the presence of systemic, cutaneous, or urinary tract infection 13
• The use of vacuum devices without a vacuum limiter is also discouraged 13

Evidence‑Based Management of Erectile Dysfunction in Older Men

1. First‑Line Pharmacotherapy

• Oral phosphodiesterase‑5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil, or avanafil) are recommended as the initial treatment for men with erectile dysfunction who are not using nitrates and have acceptable cardiovascular risk. [14][15]
• All FDA‑approved PDE5 inhibitors demonstrate similar overall efficacy, achieving successful intercourse in roughly 69 % of attempts versus 33 % with placebo. [14][15]

2. Pre‑Treatment Safety Assessment

2.1 Contraindications

• Nitrate use (including sublingual nitroglycerin, long‑acting nitrates, isosorbide mononitrate/dinitrate, or recreational “poppers”) is an absolute contraindication to PDE5 inhibitor therapy because of the risk of severe hypotension. 14

2.2 Cardiovascular Risk Stratification

• Functional cardiac capacity should be screened by asking whether the patient can walk 1 mile in ≤20 minutes or climb two flights of stairs without symptoms; this approximates the cardiac demand of sexual activity. 16
• Low‑risk patients (e.g., controlled hypertension, stable angina, successful coronary revascularization, uncomplicated prior myocardial infarction, NYHA Class I heart failure, or asymptomatic coronary artery disease with ≤3 risk factors) may safely receive PDE5 inhibitors. 16
• High‑risk patients (e.g., unstable angina, uncontrolled hypertension, recent myocardial infarction or stroke within 2 weeks, NYHA Class ≥ II heart failure, severe valvular disease, or high‑risk arrhythmias) should defer erectile‑dysfunction treatment until cardiac stability is achieved. 16
• Referral to cardiology is advised when cardiovascular risk is uncertain or when the patient cannot perform moderate physical activity. 16

2.3 Baseline Laboratory Testing

• A morning serum total testosterone measurement should be obtained before initiating PDE5 inhibitor therapy, because testosterone deficiency can diminish drug efficacy and may necessitate combined hormonal treatment. 17

3. Hormonal Evaluation and Adjunctive Testosterone Therapy

• Men with total testosterone < 230 ng/dL generally benefit from testosterone replacement therapy (TRT). 16
• For testosterone levels between 231–346 ng/dL, a 4–6‑month trial of TRT may be considered in symptomatic individuals after discussing risks and benefits. 16
• In hypogonadal men, concurrent use of TRT with a PDE5 inhibitor yields superior erectile outcomes compared with PDE5 inhibitor monotherapy. 17
• Testosterone monotherapy alone does not improve erectile function; it must be combined with a PDE5 inhibitor for efficacy.

4. Lifestyle and Modifiable Factors

• Smoking cessation is associated with improved response to PDE5 inhibitors and overall cardiovascular health. 16
• For patients older than 70 years who require TRT, easily titratable formulations (gel, spray, or patch) are preferred over long‑acting injectables. 16
• Target testosterone repletion goals in older men should aim for mid‑range levels (approximately 350–600 ng/dL) to balance efficacy with cardiovascular safety. 16

5. Second‑Line and Adjunctive Therapies (after failure of ≥2 PDE5 inhibitors at maximum tolerated dose)

• Progression to second‑line therapies should only occur after documented failure of at least two different PDE5 inhibitors at their maximum doses, after an adequate trial (≥5 attempts with proper technique) and after correction of all modifiable factors.

6. Special Considerations for the Elderly (≥75 years)

• Age alone does not require dose reduction of PDE5 inhibitors, although increased drug sensitivity should be monitored.
• In studies of men ≥65 years, tadalafil was associated with a modestly higher incidence of diarrhea (≈2.5 %) compared with younger cohorts.

All statements are supported by the cited evidence.